C. Slader

发表

Double blind randomised controlled trial of two different breathing techniques in the management of asthma

C. Jenkins, S. Bosnic-Anticevich, F. Thien, 2006, Thorax.

Enabling access to molecular monitoring for chronic myeloid leukemia patients is cost effective in China

C. Slader, Christina Gkitzia, V. Maheshwari, 2021, PloS one.

Audit of Celecoxib and Rofecoxib Use: St Vincent's Public Hospital, Darlinghurst

C. Slader, S. Welch, 2003 .

TARGET: a survey of real‐world management of chronic myeloid leukaemia across 33 countries

V. Mathews, Jianxiang Wang, G. Saydam, 2020, British journal of haematology.

Complementary and alternative medicine use in asthma: Who is using what?

C. Jenkins, S. Bosnic-Anticevich, C. Armour, 2006, Respirology.

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study.

J. Melo, A. Schwarer, J. Seymour, 2013, Blood.

Running head: Imatinib Cessation After Stable UMRD in CML

J. Melo, A. Schwarer, J. Seymour, 2017 .

Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR

J. Melo, A. Schwarer, J. Seymour, 2010, Leukemia.

Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib

J. Radich, G. Martinelli, P. Manley, 2012, Haematologica.

Non‐Pharmacological and Complementary Interventions to Manage Asthma

B. Toelle, G. Marks, C. Slader, 2007 .

Regulation of p63 function by Mdm2 and MdmX.

S. Berberich, M. Kadakia, C. Slader, 2001, DNA and cell biology.

A Phase Ib Study of Alpelisib or Buparlisib Combined with Tamoxifen Plus Goserelin in Premenopausal Women with HR-Positive HER2-Negative Advanced Breast Cancer

Yeon-Hee Park, I. Chitapanarux, K. Jung, 2020, Clinical Cancer Research.

Asthma and Complementary Therapies: A Guide for Health Professionals

Vicki Kotsirilos, G. Marks, R. Mullins, 2005 .

Selective Escalation of Imatinib Therapy and Early Switching to Nilotinib In De Novo Chronic Phase CML Patients: Interim Results From the TIDEL-II Trial

A. Schwarer, D. White, T. Hughes, 2010 .

Upfront Imatinib Therapy in CML Patients with Rapid Switching to Nilotinib for Failure to Achieve Molecular Targets or Intolerance Achieves High Overall Rates of Molecular Response and a Low Risk of Progression - An Update of the TIDEL-II Trial

A. Schwarer, D. White, T. Hughes, 2011 .

Early Switch to Nilotinib Does Not Overcome the Adverse Outcome for CML Patients Failing to Achieve Early Molecular Response On Imatinib, Despite Excellent Overall Outcomes in the TIDEL II Trial

A. Schwarer, D. White, T. Hughes, 2012 .